Can survival be prolonged for patients with hormone-resistant prostate cancer?
Zlotta
A R
AR
Department of Urology, Erasme Hospital, University Clinics of Brussels, Belgium. azlotta@ulb.ac.be
Schulman
C C
CC
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D015996:Survival Rate
D000970:Antineoplastic Agents; D013326:Strontium Radioisotopes; D004317:Doxorubicin